Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Nektar Therapeutics (0UNL) Share Price & Analysis

0 Followers

0UNL Stock Chart & Stats

$37.66-$0.14(-0.37%)
At close: 4:30 PM GMT
$40$50$60$70Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$35.78 - $38.28
52-Week Range
$28.70 - $109.01
Previous Close
$37.80
Volume
N/A
Average Volume (3M)
1,766
Market Cap
$1.27B
Enterprise Value
$1.58B
Total Cash (Recent Filing)
$614.36M
Total Debt (Recent Filing)
$73.88M
Price to Earnings (P/E)
―
Beta
0.55
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-2.49
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Liquidity And No Debt

The large cash balance and absence of debt provide meaningful funding flexibility while Nektar advances several late-stage programs. This reduces near-term financing pressure and supports continued clinical execution, although future cash needs remain tied to development spending and operating performance.

Late-stage Clinical Execution

Starting three pivotal atopic dermatitis studies represents a material transition from mid-stage validation toward potential registration. Broad enrollment across patient types can strengthen the evidence package and expand eventual label opportunities if the trials confirm REZPEG’s efficacy and safety.

Durable Clinical Responses

Sustained responses after less frequent maintenance dosing could differentiate REZPEG in chronic immune dermatology and improve its practical treatment profile. Durable disease control may support physician adoption and commercial positioning if the effect is reproduced in Phase III studies.

Bears Say

Persistent Losses And Cash Burn

Deep recurring cash burn means Nektar is consuming substantial liquidity before any potential product commercialization. Continued losses can constrain strategic flexibility and may eventually require additional financing or business development unless clinical progress leads to durable revenue generation.

Contracting And Collaboration-driven Revenue

The declining revenue base highlights limited recurring commercial income and leaves results exposed to collaboration timing, milestones, royalties, and partner decisions. Until a pipeline asset reaches market, revenue visibility is likely to remain less predictable than that of a product-led biotechnology company.

Long Path To Potential Approval

The extended development timeline delays potential commercial revenue and leaves value creation dependent on several future clinical and regulatory milestones. Two successful Phase III studies are required for registration, so setbacks could prolong losses and materially defer the company’s transition to commercialization.

Nektar Therapeutics News

0UNL FAQ

What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest share price was $28.70 and its highest was $109.01 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $1.27B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 108 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Nov 12, 2026. The company reported -$1.63 earnings per share for the quarter, beating the consensus estimate of -$2.069 by $0.439.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Nektar Therapeutics dividends here
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.49.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 34,142,994 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.63 in its last earnings report, beating expectations of -$2.069. Following the earnings report the stock price went down -0.37%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Hedge funds hold Nektar Therapeutics shares: the largest hedge-fund position in Nektar Therapeutics is 1,065,734,801 shares, and hedge funds increased their holdings by 443.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology